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Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30),
a PRO instrument specifically designed to measure HRQoL of cancer patients.
HRQoL was measured at screening, months 1, 3, 7, and at re-puncture. Meaningful
deterioration was defined as a decrease in HRQoL scores of at least 5 points. Time
to first meaningful deterioration was compared between catumaxomab (N160)
and control (N85) groups using survival analysis techniques such as log-rank test
and Cox models. RESULTS: Deterioration in HRQoL scores appeared more rapidly
in the control group than the catumaxomab group (medians: 16-28 days vs. 45-49
days). The difference between the two groups in time to deterioration in HRQoL
was statistically significant for all scores (p0.01). Results were confirmed with Cox
models (p0.05). Hazard ratios ranged from 0.08 to 0.24.CONCLUSIONS:Treatment
with catumaxomab delayed deterioration in HRQoL in patients with MA compared
to paracentesis alone. The findings of this study indicate that the gain of puncture
free survival due to catumaxomab treatment previously reported (Heiss et al. 2010)
translates into a HRQoL benefit for the patients.
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OBJECTIVES: The majority of patients with prostate cancer progress to CRPC and
frequently develop bone metastases. Treatment and management of bone metas-
tases, as well as the underlying disease, influences the patient’s quality of life. We
evaluated the impact of bone metastases on utility (using EQ-5D) and quality of life
(using FACT-P) in high-risk CRPC patients. METHODS: Data were extracted from
the Adelphi Real World Prostate Cancer Disease-Specific Programme© (DSP), a
cross-sectional survey of 348 urologists and oncologists and their prostate cancer
patients that was conducted between December 2009 and May 2010 in France,
Germany, Italy, Spain and the UK. Physicians completed comprehensive record
forms on 10 patients being actively treated for prostate cancer. Patients could also
complete a questionnaire, which included the EQ-5D and FACT-P tools, however
this was not compulsory. RESULTS:Of the 3,477 prostate cancer patients for which
data were collected, 1,180 (34%) were categorised as having CRPC with a median
time since diagnosis of 35.8 months. 146 patients with CRPC were identified as
being at high risk for developing bone metastases (Gleason score 8, or a most
recent PSA of 8ng/mL, or a PSA DT 10 months, or had received local therapy in
addition to systemic medication). High-risk CRPC patients had an average EQ-5D
index of 0.77 (n36) and FACT-P of 99.54 (n27). In contrast, patients with CRPC
and bone metastases (n680) had an average EQ-5D index of 0.59 (n165) and
FACT-P of 82.99 (n147). Statistical differences were observed between the high-
risk and bone metastases groups for both EQ-5D (p0.0002) and FACT-P (p0.0007).
CONCLUSIONS: The development of bone metastases represents a significant ad-
ditional burden for patients with CRPC highlighting the need for new treatments
capable of preventing bone metastases in these patients.
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OBJECTIVES: (1) To identify antineoplastic agents approved with a PRO labeling
claim in Europe and the USA; (2) To review the types of PROs used for these ap-
provals; and (3) To list the differences found between Europe and the USA in terms
of products and labeling. METHODS: The search was performed on the FDA and
EMA approved medicinal product labels (from 1995 to 2010). The review was con-
ducted through a systematic manual review of antineoplastic product labelings. All
documents were read individually by two independent raters. RESULTS: A total of
138 antineoplastic products were retrieved: 55 approved by the EMA, 83 by the FDA.
Nineteen products with a PRO claim were identified: eight the USA, 11 in Europe.
Most of the PROs identified in the claims were symptoms or function. HRQL was
mentioned for 11 products: nine in Europe, two in the USA. PROs were primary
endpoints in two cases (advanced cancers). Nine products approved by both agen-
cies showed discrepancies in terms of PRO labeling: the EMA gave a PRO claim to
eight products, but not the FDA; and the FDA gave a PRO claim to one product, but
not the EMA. In most cases, the reviews of both agencies were conducted on the
same material. The comparison of the products with a PRO labeling claim approved
by the EMA but refused by the FDA showed that the FDA questioned the quality of
the study design, the analyses, or the questionnaires’ content validity.
CONCLUSIONS: Our review showed that the patients’ perspective in clinical onco-
logic research is important for the EMA and FDA. However, the patients’ perspec-
tive is not considered sufficient on its own: PROs are rarely used as primary end-
points except for assessing palliative response. Our analysis suggests that there is
high receptivity of EMA to HRQL as a concept.
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Treatment of metastatic castration-resistant prostate cancer (mCRPC) is primarily
palliative and patients’ quality of life (QoL) is considered an important treatment
goal. Nevertheless, little is known about QoL of mCRPC patients. OBJECTIVES: To
assess QoL outcomes in mCRPC patients in Germany. METHODS: 1-year observa-
tional, cross-sectional, prospective study conducted in Germany by 37 prostate-
cancer (PC) specialised centres. The study included patients with confirmed PC
diagnosis and metastatic castration-resistant disease. EQ-5D and FACT-P ques-
tionnaires were completed by patients at inclusion visit. Patient characteristics
were collected by physicians. Interim results based on 101 of 281 patients in total,
are presented. RESULTS: Mean age was 73.2 years. At inclusion, 32.6% had never
been treated with chemotherapy (no CT), 36.8% had been treated with chemother-
apy previously (past CT) and 30.5% were currently undergoing chemotherapy (on-
going CT). Mean time since PC diagnosis was 7.2 years (respectively 8.7, 6.6 and 4.0
years for no CT, past CT and ongoing CT). 34.0% of patients had metastases at
diagnosis. Mean (SD) EQ-5D single index utility score was 0.72 (0.30) (respectively
0.81 (0.27), 0.66 (0.30), 0.64 (0.31) for no CT, past CT and ongoing CT). 67.3% of
patients exhibited pain or discomfort, 58.1% problems to perform usual activities,
53.1% mobility problems, 37.7% anxiety/depression troubles and 32.7% self-care
problems. Mean (SD) EQ-5D VAS score was 47.8 (23.6). Mean (SD) FACT-P total score
was 101.5 (25.2) (respectively 106.0 (27.1), 95.2 (21.6) and 103.5 (26.7) for no CT, past
CT and ongoing CT). Mean (SD) subscale scores were: physical well-being: 19.5 (6.6),
social/family well-being: 20.6 (5.6), emotional well-being: 17.0 (4.8), functional well-
being: 15.7 (6.3) and PC subscale: 28.6 (9.0). CONCLUSIONS: The interim analysis
provides first trends on QoL in German mCRPC patients. Final analyses are ex-
pected to clarify determinants of QoL and in particular the impact of chemother-
apy.
PCN121
DECITABINE REDUCES TRANSFUSION DEPENDENCE IN OLDER PATIENTS WITH
ACUTE MYELOID LEUKAEMIA: RESULTS FROM A POST-HOC ANALYSIS OF A
RANDOMISED PHASE III TRIAL
Dass RN1, Howes A1, Spencer M2, Xiu L3, Thomas XG4, Al-Dakkak I5
1Janssen-Cilag Limited, High Wycombe, UK, 2Janssen-Cilag Limited, High Wycombe, Bucks, UK,
3Janssen-Cilag Limited, Raritan, NJ, USA, 4Centre Hospitalier Lyon Sud, Pierre-Benite cedex,
France, 5HERON Health, Luton, UK
OBJECTIVES: The incidence of acute myeloid leukaemia (AML) increases with age;
older patients have limited treatment options and poorer outcomes. Dependence
on blood transfusions (correcting anaemia and preventing bleeding) and repeated
hospitalisation reduce health-related quality of life and increase treatment expen-
diture. This post-hoc analysis assessed the impact of decitabine on transfusion
dependence.METHODS:The DACO-16 phase III trial (NCT00260832) was conducted
in newly-diagnosed AML patients (65 years; N485) (Kantarjian, JCO; ePub
11Jun2012). Every 4 weeks, patients received decitabine (DACOGEN) 20 mg/m2 (1-h
intravenously; 5 successive days) or treatment choice with physician’s advice (TC)
with supportive care or cytarabine (20 mg/m2 subcutaneously daily; 10 successive
days). Treatment duration was longer in the DACOGEN than TC arm (median: 4
cycles vs. 2 cycles). We measured red blood cell (RBC) and platelet (PLT) transfu-
sion-independence (no transfusions for 8 consecutive weeks) and hospitalisation
length (% hospital nights relative to treatment days) in both DACOGEN (n242) and
TC (n243) arms. RESULTS: In patients who were PLT transfusion-dependent at
baseline (85 in DACOGEN and 83 in TC arms), more became transfusion-indepen-
dent in the DACOGEN arm (26 [31%]) than the TC arm (11 [13%]) (p0.0069). Like-
wise, in RBC transfusion-dependent patients at baseline (168 in DACOGEN and 162
in TC arms), transfusion-independence was higher for DACOGEN (44 [26%]) than TC
(21 [13%]) (p0.0026). For hospitalised patients (182 in TC, 191 in DACOGEN arms),
the median % of hospital nights was higher in the TC arm (39%) than the DACOGEN
arm (34%). Similarly, for adverse event-hospitalised patients (100 in TC, 132 in
DACOGEN arms), the median was 20.0% vs. 17.5% in the TC and DACOGEN arms,
respectively. CONCLUSIONS: Dacogen leads to a statistically-significant reduction
in transfusion-dependence, when compared with TC. This reduction is an impor-
tant factor in the economic and humanistic burden of AML in older patients.
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OBJECTIVES: G-CSFs can decrease the incidence of febrile neutropenia (FN) among
cancer patients receiving highly myelosuppressive chemotherapy regimens. The
primary objective of this pilot study was to determine the feasibility of a discrete
choice survey on prophylactic G-CSF (pegfilgrastim and filgrastim) use in patients
diagnosed with breast cancer as well as refine the survey instrument before pro-
ceeding with the full study population. METHODS: A web-based discrete choice
survey of patients diagnosed with breast cancer, and previously treated with che-
motherapy, was conducted. The pilot survey was developed based on literature
review, clinical consultation and 6 in-depth and 4 pre-test interviews with breast
cancer patients. The experimental design was generated using Sawtooth software
with 16 paired treatment-scenarios, comparing pegfilgrastim to filgrastim at 6- or
11-doses with a follow-up “no treatment” option. The 5 attributes included: fre-
quency of treatment, inconvenience of treatment, risk of disruption to chemother-
apy schedule due to low white blood cell counts, risk of developing an infection
requiring hospitalization, and patient out-of-pocket cost. Demographics, clinical
characteristics, health care costs and attitudinal data were also collected.
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